EU/3/17/1860

Table of contents

About

On 20 March 2017, orphan designation (EU/3/17/1860) was granted by the European Commission to Viadoc Business Solutions Limited, United Kingdom, for poly-cyclodextrin-bis-cysteine-PEG3400-camptothecin-conjugate (also known as CRLX101) for the treatment of ovarian cancer.

Key facts

Active substance
Poly-cyclodextrin-bis-cysteine-PEG3400-camptothecin-conjugate
Disease / condition
Treatment of ovarian cancer
Date of first decision
20/03/2017
Outcome
Positive
EU designation number
EU/3/17/1860

Sponsor's contact details

Viadoc Business Solutions Limited
C/O Oakwood Corporate Services
1 Ashley Road, 3rd floor
Altrincham, Cheshire
WA14 2DT
United Kingdom
Tel. +44 (0)161 942 4702
E-mail: patti@viadoc.net

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating